Nicotine and epibatidine alter differently nomifensine-elevated dopamine output in the rat dorsal and ventral striatum

Sanna Janhunen, Raimo K Tuominen, Timo Petteri Piepponen, Liisa Ahtee

    Research output: Contribution to journalArticleScientificpeer-review

    Abstract

    We studied the effects of nicotine and epibatidine given in combination with dopamine uptake inhibitor, nomifensine, on striatal extracellular dopamine and its metabolites by using brain microdialysis in freely moving rats. Nomifensine (3 mg/kg) elevated extracellular dopamine in the caudate-putamen, and clearly more in the nucleus accumbens. In the caudate-putamen, nicotine (0.5 mg/kg) and epibatidine (0.6 mu g/kg but not 3.0 mu g/kg) enhanced nomifensine's effect on dopamine. The effect of nomifensine on accumbal dopamine was enhanced by nicotine, but inhibited by epibatidine at 0.6 mu g/kg. The larger dose of epibatidine had no effect. Thus, the effects of the smaller epibatidine dose (0.6 mu g/kg) on the dopamine output in the caudate-putamen but not in the accumbens resemble those of nicotine 0.5 mg/kg. Discrepancies in the effects of epibatidine and nicotine are most probably due to differences in their affinities to nicotinic receptor subtypes regulating dopamine release. Further, different responses to low concentrations of epibatidine between the brain areas suggest that there are differences in the nicotinic regulation of nigrostriatal and mesolimbic dopaminergic pathways. (c) 2005 Elsevier B.V. All rights reserved.
    Original languageEnglish
    JournalEuropean Journal of Pharmacology
    Volume511
    Issue number2-3
    Pages (from-to)143-50
    Number of pages8
    ISSN0014-2999
    DOIs
    Publication statusPublished - 2005
    MoE publication typeA1 Journal article-refereed

    Fields of Science

    • nikotiini
    • reseptorit
    • dopamiini
    • Parkinsonin tauti
    • 317 Pharmacy

    Cite this

    @article{5839cbd35e0c470785fa7ff85902350a,
    title = "Nicotine and epibatidine alter differently nomifensine-elevated dopamine output in the rat dorsal and ventral striatum",
    abstract = "We studied the effects of nicotine and epibatidine given in combination with dopamine uptake inhibitor, nomifensine, on striatal extracellular dopamine and its metabolites by using brain microdialysis in freely moving rats. Nomifensine (3 mg/kg) elevated extracellular dopamine in the caudate-putamen, and clearly more in the nucleus accumbens. In the caudate-putamen, nicotine (0.5 mg/kg) and epibatidine (0.6 mu g/kg but not 3.0 mu g/kg) enhanced nomifensine's effect on dopamine. The effect of nomifensine on accumbal dopamine was enhanced by nicotine, but inhibited by epibatidine at 0.6 mu g/kg. The larger dose of epibatidine had no effect. Thus, the effects of the smaller epibatidine dose (0.6 mu g/kg) on the dopamine output in the caudate-putamen but not in the accumbens resemble those of nicotine 0.5 mg/kg. Discrepancies in the effects of epibatidine and nicotine are most probably due to differences in their affinities to nicotinic receptor subtypes regulating dopamine release. Further, different responses to low concentrations of epibatidine between the brain areas suggest that there are differences in the nicotinic regulation of nigrostriatal and mesolimbic dopaminergic pathways. (c) 2005 Elsevier B.V. All rights reserved.",
    keywords = "nikotiini, reseptorit, dopamiini, Parkinsonin tauti, nikotiini, reseptorit, dopamiini, Parkinsonin tauti, nikotiini, reseptorit, dopamiini, Parkinsonin tauti, 317 Pharmacy",
    author = "Sanna Janhunen and Tuominen, {Raimo K} and Piepponen, {Timo Petteri} and Liisa Ahtee",
    year = "2005",
    doi = "10.1016/j.ejphar.2005.02.017",
    language = "English",
    volume = "511",
    pages = "143--50",
    journal = "European Journal of Pharmacology",
    issn = "0014-2999",
    publisher = "Elsevier Scientific Publ. Co",
    number = "2-3",

    }

    Nicotine and epibatidine alter differently nomifensine-elevated dopamine output in the rat dorsal and ventral striatum. / Janhunen, Sanna; Tuominen, Raimo K; Piepponen, Timo Petteri; Ahtee, Liisa.

    In: European Journal of Pharmacology, Vol. 511, No. 2-3, 2005, p. 143-50.

    Research output: Contribution to journalArticleScientificpeer-review

    TY - JOUR

    T1 - Nicotine and epibatidine alter differently nomifensine-elevated dopamine output in the rat dorsal and ventral striatum

    AU - Janhunen, Sanna

    AU - Tuominen, Raimo K

    AU - Piepponen, Timo Petteri

    AU - Ahtee, Liisa

    PY - 2005

    Y1 - 2005

    N2 - We studied the effects of nicotine and epibatidine given in combination with dopamine uptake inhibitor, nomifensine, on striatal extracellular dopamine and its metabolites by using brain microdialysis in freely moving rats. Nomifensine (3 mg/kg) elevated extracellular dopamine in the caudate-putamen, and clearly more in the nucleus accumbens. In the caudate-putamen, nicotine (0.5 mg/kg) and epibatidine (0.6 mu g/kg but not 3.0 mu g/kg) enhanced nomifensine's effect on dopamine. The effect of nomifensine on accumbal dopamine was enhanced by nicotine, but inhibited by epibatidine at 0.6 mu g/kg. The larger dose of epibatidine had no effect. Thus, the effects of the smaller epibatidine dose (0.6 mu g/kg) on the dopamine output in the caudate-putamen but not in the accumbens resemble those of nicotine 0.5 mg/kg. Discrepancies in the effects of epibatidine and nicotine are most probably due to differences in their affinities to nicotinic receptor subtypes regulating dopamine release. Further, different responses to low concentrations of epibatidine between the brain areas suggest that there are differences in the nicotinic regulation of nigrostriatal and mesolimbic dopaminergic pathways. (c) 2005 Elsevier B.V. All rights reserved.

    AB - We studied the effects of nicotine and epibatidine given in combination with dopamine uptake inhibitor, nomifensine, on striatal extracellular dopamine and its metabolites by using brain microdialysis in freely moving rats. Nomifensine (3 mg/kg) elevated extracellular dopamine in the caudate-putamen, and clearly more in the nucleus accumbens. In the caudate-putamen, nicotine (0.5 mg/kg) and epibatidine (0.6 mu g/kg but not 3.0 mu g/kg) enhanced nomifensine's effect on dopamine. The effect of nomifensine on accumbal dopamine was enhanced by nicotine, but inhibited by epibatidine at 0.6 mu g/kg. The larger dose of epibatidine had no effect. Thus, the effects of the smaller epibatidine dose (0.6 mu g/kg) on the dopamine output in the caudate-putamen but not in the accumbens resemble those of nicotine 0.5 mg/kg. Discrepancies in the effects of epibatidine and nicotine are most probably due to differences in their affinities to nicotinic receptor subtypes regulating dopamine release. Further, different responses to low concentrations of epibatidine between the brain areas suggest that there are differences in the nicotinic regulation of nigrostriatal and mesolimbic dopaminergic pathways. (c) 2005 Elsevier B.V. All rights reserved.

    KW - nikotiini

    KW - reseptorit

    KW - dopamiini

    KW - Parkinsonin tauti

    KW - nikotiini

    KW - reseptorit

    KW - dopamiini

    KW - Parkinsonin tauti

    KW - nikotiini

    KW - reseptorit

    KW - dopamiini

    KW - Parkinsonin tauti

    KW - 317 Pharmacy

    U2 - 10.1016/j.ejphar.2005.02.017

    DO - 10.1016/j.ejphar.2005.02.017

    M3 - Article

    VL - 511

    SP - 143

    EP - 150

    JO - European Journal of Pharmacology

    JF - European Journal of Pharmacology

    SN - 0014-2999

    IS - 2-3

    ER -